Compare MFP & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFP | ZYME |
|---|---|---|
| Founded | 2025 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2025 | 2022 |
| Metric | MFP | ZYME |
|---|---|---|
| Price | $44.85 | $30.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $46.67 | $41.50 |
| AVG Volume (30 Days) | 409.1K | ★ 1.3M |
| Earning Date | 11-17-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $11.60 | $176.93 |
| Revenue Next Year | $6.07 | $28.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $38.51 | $18.20 |
| 52 Week High | $52.58 | $31.49 |
| Indicator | MFP | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 60.86 | 63.37 |
| Support Level | $39.58 | $22.04 |
| Resistance Level | $46.15 | $31.34 |
| Average True Range (ATR) | 2.04 | 1.19 |
| MACD | 0.36 | 0.22 |
| Stochastic Oscillator | 97.62 | 82.79 |
Midera Food Processing Inc provides food processing equipment and automation solutions for industrial protein, bakery, and snack producers, delivering total line solutions from preparation and thermal processing through packaging. The company operates through a portfolio of brands and serves food processors globally. It serves various international food processing companies and producers of protein products, such as bacon, charcuterie, sausage and hot dogs, egg bites, poultry, alternative protein, lunch meat and pet food, and producers of bakery products, such as bread and buns, artisan bread, cakes and muffins, etc. The company generates revenue from the design, manufacturing and installation of food processing equipment and technology solutions and aftermarket parts and service.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.